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Endothelm-1 (ET-l) is known to stimulate phospholipase C (PLC) activity m SK-N-MC human neuroblastoma/epithehoma cells: here we show 
that phospholipase D (PLD) is also stimulated. The generation of inosttol 1.4,5-trtsphosphdte (Ins(1,4,5)P,) by ET-l-stimulated PLC was attenuated 
by protein kinase C (PKC) activation and enhanced by PKC inhibition, An enhancement of ET-l-stimulated Ins( 1,4,5)P, accumulation was also 
seen when the product of PLD activity was either diverted into phosphatidyl butanol m the presence of butanol, or phosphatidate phosphohydrolase 
(PPH) activity was inhibited by or-propranolol. We conclude that there is an inhibitory. PKC-mediated. feedback loop in these cells which is 
dependent, in part, on the activation of PKC by product(s) of the PLD/PPH pathway. Thts provides a novel role for agonist-sttmulated PLD 
activation. 
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1. INTRODUCTION 
Inositol phospholipid hydrolysis by agonist-stimu- 
lated phosphoinositide-specific phospholipase C (PLC) 
has been shown to be modulated by protein kinase C 
(PKC) in many systems. For example, direct activation 
of PKC by phorbol esters has been shown to decrease, 
whilst PKC inhibition or down-regulation can facili- 
tate, agonist-stimulated inositol 1,4.5-trisphosphate 
(Ins( 1,4,5)P,) accumulation [14]. Such data are 
strongly suggestive of the existence of a short negative 
feedback loop by which PKC activation attenuates ag- 
onist-stimulated PLC activity. 
In many cases of stimulation of PLC by receptors it 
has been reported that phospholipase D (PLD) activa- 
tion also occurs. It seems very likely that PLD activa- 
tion commonly occurs downstream of PLC: in a num- 
ber of instances this has been shown to involve PKC 
[5-71. The primary lipid product of PLD is phosphatidic 
acid (PtdOH) which may be converted to diacylglycerol 
by phosphatidate phosphohydrolase (PPH), and so the 
PLD route may serve as an alternative, agonist-acti- 
vated pathway for stimulation of PKC. Despite various 
suggestions for a second messenger role for PtdOH it- 
self, and intense interest in the PLD/PPH pathway, 
there is no established role for PLD in short-term cell 
signalling processes. 
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Here we investigate signalling events in a human neu- 
roblastoma/epithelioma-derived cell line (SK-N-MC) 
stimulated by endothelin-1 (ET-l) acting on ET, recep- 
tors which are linked to PLC [8,9]. We show that the 
PLC response is profoundly attenuated by a short PKC 
inhibitory loop, and provide evidence that this feedback 
loop is activated by a product of agonist-stimulated 
PLD. 
2. MATERIALS AND METHODS 
2.1 Muterials 
ET-l was purchased from the Peptide Research Institute (Osaka, 
Japan). Ro 31-8220 was a kmd gift of Dr. G. Lawton, Roche Products 
Ltd. (Welwyn. UK). Cell culture supplies were from Gibco (Paisley, 
Scotland). Other chemicals were from Sigma or Fisons. “P, was from 
Amersham and nzyo-[2-‘Hlinositol and [‘H]Ins( 1,4.5)P, were from 
NEN-DuPont. 
2.2. 12Pr labelling und PLD assay 
The procedures for labelling cells with 32P, and subsequent analysis 
have been described and validated by Purkiss and Boarder [7]. Briefly. 
SK-N-MC cells (passage 55-60) were loaded with “P) (0.25 MBq/ml) 
m 0.4 ml of a phosphate-free balanced salt solution for 24 h. The 
loading medium was replaced wtth 0 5 ml balanced salt solution. and 
after 10 min. the medium was again replaced by fresh medmm contam- 
ing ET-l and butanol. Where appropriate additions of 12-O-tetrade- 
canoyl-phorbol 13 acetate (TPA) and/or Ro 31-8220 were present 
throughout the incubation period. Incubattons were terminated with 
methanol/CHCl,. [“PlPhosphattdylbutanol (PtdBut). which is a 
unique product of PLD and thus an index of PLD activity, was 
separated by thin layer chromatography. 
2.3. Measurement of total [‘H]mosaol phosphates and Ins(1,4.5jP3 
For assessment of [3H]mositol phosphate ([‘H]InsP,) production, 
cells were loaded for 48 h with [‘Hlinositol (0.074 MBq/ml) in 0.5 ml 
Dulbecco’s modified Eagle’s medium with 1% non-essenttal ammo 
acids. After washing, cell monolayers were premcubated for 10 min 
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wtth 10 mM LiCI, whtch was also present during the 30 mm incubation 
period wtth ET-l. Where indicated additions of TPA. Ro 31-8220. 
butanol and m-propranolol were made to both pre-incubation and 
incubation media. Incubations were terminated wtth cold acidified 
methanoUCHC1,. [‘H]InsP, were separated by Dowex-I (Cl- form) ion 
exchange chromatography. For experiments where Ins( 1,4,5)P, mass 
was measured, unlabelled cells were prc-incubated/incubated as de- 
scribed above except that LiCl was omitted and incubations were 
terminated by medium aspiration and addition of 0.5 M trichlo- 
roacetic acid. Samples were processed and Ins( 1.4.5)P, determined as 
described previously [IO]. 
3. RESULTS AND DISCUSSION 
Preliminary experiments established that an ET-l - 
stimulated increase in [3’P]PtdBut accumulation could 
be demonstrated in SK-N-MC cells pre-labelled with 
“P, and stimulated in the presence of 50 mM butanol. 
The effect of ET-l (l-100 nM) was shown to be concen- 
tration-dependent. with a 288 + 45% stimulation of 
[“‘P]PtdBut accumulation being observed in response to 
100 nM ET-l; time-course studies revealed a plateau in 
[3’P]PtdBut accumulation by 335 min. ET- 1 -stimulated 
[“‘P]PtdBut accumulation (3 min incubations) was at- 
tenuated in the presence of the protein kinase C inhibi- 
tor Ro 318220; furthermore, addition of phorbol ester 
alone did not increase [“P]PtdBut accumulation (e.g. 
control, 311 & 38; + ET-l ( 100 nM), 736 + 87; + ET- 
1 + Ro 31-8330 ( 10 yM), 466 & 50; + TPA ( 100 nM), 
264 + 16 d.p.m./well: mean ? S.E.M. for one represen- 
tative experiment of three performed in triplicate). 
These results show that ET-l can stimulate PLD activ- 
ity at similar concentrations to those previously shown 
to cause PLC activation in this cell line [9], and that 
stimulation of PKC is necessary, but not sufficient, for 
PLD activation. 
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Fig. 1. Effects of Ro 31-8220 and butanol on ET-1-sttmulated 
Ins( I ,4,5)P, accumulation in SK-N-MC cells. Cells were pre-incubated 
for 10 mm m the presence of IO PM Ro 31-8220 or 50 mM butanol 
before addition of 100 nM ET-l. Data points shown represent 
means 2 S.E.M for 4 separate experiments performed m triphcate. 
Symbols represent: i). no addition, l , + ET-l, n . + ET-I/R0 31-8220, 
and t. + ET-l/butanol. 
Table I 
Effects of Ro 31-8220 and TPA on basal and ET-I-sttmulated 
[‘H]InsP, and Ins( 1.4.5)P, accumulation m SK-N-MC cells 
No addition Ro 31-8220 TPA 
(lO,uM) (100 nM) 
(a) [ZH]InsP, accumulation (dpmlwell) 
Basal 2.963 * 222 5.05‘4 f 491 3.443 * 104 
+ ET-I (100 nM) 5.389 f 129 13,366 k 663 3,802 + 299 
(b) Ins(1,4,5)P, accumulation (pmol/well) 
Basal 2.94 + 0.33 3.95 k 0.60 3.39 k 0 58 
+ ET-l (100 nM) 9.09 2 0.49 25.42 i- 7 23 3 94 + 0 24 
For (a) values are means + S.E.M. for a single representative expert- 
ment. performed on three other occastons with simtlar results. SK-N- 
MC cells were pre-incubated wtth either Ro 31-8220 or TPA. plus IO 
mM LtCl for 10 mm before additton of ET-I or vehicle for 30 min. 
For (b) values are means k S.E M. for at least 3 expertments per- 
formed m triplicate. Prc-mcubatton wtth either Ro 31-8220 or TPA 
for 10 mm was followed by ET-1 challenge for 5 mm. Ro 31-8220 
stgmficantly enhanced basal [‘H]InsP, accumulation (P < 0.05). but 
not Ins(1.4.5)P, accumulatton. For both (a) and(b) Ro 31-8220 sigmf- 
scantly enhanced (P < 0 01). and TPA stgmficantly attenuated 
(P < 0.05) the ET-I-sttmulated response (Student’s t-test) 
Experiments using [3H]inositol-labelled cells and 
measurement of total [3H]InsP, as an index of PLC 
activity (Table I) show that both basal and ET-l-stimu- 
lated [3H]InsP, accumulations were increased in the 
presence of Ro 31-8220. TPA had no effect on basal 
vH]InsP,, but substantially attenuated the agonist-stim- 
ulated increase in [‘H]InsP, accumulation. These results 
suggest that activation of PKC can inhibit ET-l-stimu- 
lated PLC activity, and both basal and agonist-stimu- 
lated PLC activity may be under tonic inhibitory feed- 
back control by PKC. 
These conclusions are supported and strengthened by 
experiments where changes in Ins( 1.4,5)P, mass levels 
were measured. Time-course studies established that 
ET-l (100 nM) caused a sustained 3-fold increase in 
Ins( 1,4,5)P, accumulation (Fig. 1). In the presence of a 
maximally-effective concentration of the PKC inhibitor 
Ro 31-8220 (10 PM) a substantial enhancement of 
Ins( 1,4,5)P, accumulation was observed (Fig. 1); thus at 
5 min after ET-l addition the increase in Ins( 1,4,5)P, 
accumulation was 350% greater in the presence of Ro 
31-8220 compared to the effect of ET-l alone (Table I). 
In contrast to the data shown for [3H]InsP, accumula- 
tion, Ro 3 l-8220 alone had no significant effect on basal 
Ins( 1,4,5)P, levels (Table I). TPA (100 nM) had no ef- 
fect on basal Ins( 1,4,5)P, levels, but abolished the ET- 
l-stimulated increase in Ins( 1,4,5)P, accumulation 
(Table I). These data clearly show that inhibition of 
PKC activity dramatically increases the Ins( 1,4.5)P, ac- 
cumulation attained in the presence of ET-I. whilst ad- 
dition of an exogenous activator of PKC can essentially 
abolish agonist-stimulated Ins( 1.4,5)P, accumulation, 
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Fig. 2. Effects of m-propranolol and butanol on ET-l-stimulated 
Ins( 1,4,5)P, accumulation in SK-N-MC cells. Cells were pre-incubated 
for 10 min m the presence of 300 ,uM oL-propranolol (striped bars), 
50 mM butanol (filled bars) or no pre-addition (open bars) before 
addition of 100 nM ET-1 at zero-time. Columns represent 
means f S.E.M. for 3 separate experiments performed in triplicate. 
Statistically significant (Student’s r-test) enhancements of the 
Ins(1,4,5)P, accumulation over those caused by ET-1 only are indi- 
cated as *P < 0.05: **P c 0.01. 
establishing the existence of a short inhibitory feedback 
loop between PKC and PLC in SK-N-MC cells. 
Further experiments to investigate the possible regu- 
latory role of products of PLD activation were under- 
taken using either butanol (50 mM) to divert PLD cat- 
alysed formation of PtdOH to PtdBut, or oL-propra- 
nolo1 (300 PM) to inhibit PPH and thus prevent the 
conversion of PtdOH to diacylglycerol. 
In the presence of 50 mM butanol, ET-l-stimulated 
Ins( 1,4,5)P, accumulation was enhanced at all but the 
earliest (10 s) time-point (Figs. 1 and 2). This enhance- 
ment was characteristically 30-50s of that observed in 
the presence of Ro 31-8220 (Fig. 1). Butanol (50 mM) 
alone had no effect on basal levels of Ins( 1,4,5)P, (Fig. 
2). Preliminary experiments showed that the enhance- 
ment of the ET-l response was concentration-depend- 
ent with respect to butanol and was maximal at a bu- 
tanol concentration of 30 mM, in good agreement with 
the butanol concentration-dependency for maximal 
[3’P]PtdBut formation in 32P,-loaded cells (data not 
shown). It should also be noted that the enhancement 
of ET- 1 -stimulated Ins( 1,4,5)P, accumulation by Ro 3 l- 
8220 was similar in the presence and absence of butanol 
(ET-l/R0 31-8220, 25.4 + 2.2; ET-l/R0 31-8220/bu- 
tanol, 27.0 + 2.2 pmol Ins(l,4,5)P,/well 5 min after ag- 
onist challenge for 3 experiments performed in tripli- 
cate). 
DL-Propranolol (300 PM) exerted effects on ET-l- 
stimulated Ins( 1,4,5)P, accumulation which were com- 
parable to those of butanol (Fig. 2). Each agent signifi- 
cantly enhanced the Ins(1,4,5)P, response at 30 and 60 
s after ET-l challenge. However, whereas the butanol 
effect was maintained over the 5 min time-course, the 
propranolol enhancement decreased with time. 
At the concentration necessary for complete diver- 
sion of PLD activity towards PtdBut formation, bu- 
tanol might be expected to have diverse effects; how- 
ever, we have previously shown that where PLD is not 
activated as a consequence of agonist stimulation, bu- 
tanol at 50 mM does not affect PLC regulation [ 111. The 
specificity of 300 PM m-propranolol is less certain, with 
the recent demonstration that this agent may also have 
a direct PKC inhibitory action [12]. Despite these cave- 
ats, the results of this study are consistent with the 
hypothesis that the effects of butanol and propranolol 
are to prevent PtdOH/diacylglycerol formation and 
thus PKC activation by products of the PLD/PPH path- 
way. Since butanol and propranolol would have oppos- 
ing effects on PtdOH derived from PLD activity, it 
would appear unlikely that PtdOH (rather than dia- 
cylglycerol) can be responsible for the effects seen here. 
Furthermore, the lack of effect of butanol. compared to 
the significant enhancement of ET- 1 -stimulated 
Ins( 1,4,5)P, accumulation caused by Ro 31-8220, at the 
earliest time-point studied (10 s) may reflect a slightly 
delayed onset of action for PKC activation by dia- 
cylglycerol derived via the PLD/PPH route. These data 
therefore provide novel evidence in support of the no- 
tion that PLD activation downstream of agonist-stimu- 
lated PLC can contribute to the mechanism whereby 
PKC can regulate PLC activity by an inhibitory feed- 
back loop. 
Many reports have demonstrated diacylglycerol for- 
mation as a consequence of PLD/PPH pathway activity 
following agonist stimulation. However, the ability of 
diacylglycerol from this source to activate PKC has 
been a matter of some dispute. Recently, Lin et al. [13] 
have reported that PLD-derived diacyl-glycerol does 
not initiate PKC activation, but plays an important role 
in maintaining PKC activation in a mast cell line. Fur- 
thermore. in the same cell line, Ozawa et al. [14] have 
provided evidence that both cx and E isoforms of PKC 
are responsible for feedback inhibition of inositol phos- 
pholipid hydrolysis. However, Pachter et al. [15] have 
demonstrated that over-expression of the /?l isoform of 
PKC in rat-6 fibroblasts increases PLD activity in the 
presence of thrombin, whilst dramatically attenuating 
PLC activation. implicating the Bl isoform as a poten- 
tial mediator of the inhibitory feedback circuit. Consid- 
ering these findings in the light of our own data, it is 
tempting to speculate that different isoforms of PKC 
may be involved in the inhibition of inositol phospho- 
lipid hydrolysis depending on the relative generation of 
diacylglycerol from PLC- and PLD-derived sources. 
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